Enanta/$ENTA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Enanta
Enanta Pharmaceuticals Inc is an American biotechnology company which uses robust, chemistry-driven approach and drug discovery capabilities to focus on the research and development of molecule drugs to cure viral infections and liver diseases. Uses virology and immunology method for curing the diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.
Ticker
$ENTA
Sector
Primary listing
Employees
131
Headquarters
Website
Enanta Metrics
BasicAdvanced
$307M
-
-$4.32
0.84
-
Price and volume
Market cap
$307M
Beta
0.84
52-week high
$15.34
52-week low
$4.09
Average daily volume
1.1M
Financial strength
Current ratio
4.999
Quick ratio
4.769
Long term debt to equity
223.198
Total debt to equity
261.227
Interest coverage (TTM)
-12.29%
Profitability
EBITDA (TTM)
-92.729
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-141.98%
Operating margin (TTM)
-149.40%
Effective tax rate (TTM)
2.18%
Revenue per employee (TTM)
$490,000
Management effectiveness
Return on assets (TTM)
-17.29%
Return on equity (TTM)
-80.64%
Valuation
Price to revenue (TTM)
3.62
Price to book
2.97
Price to tangible book (TTM)
2.97
Price to free cash flow (TTM)
-5.384
Free cash flow yield (TTM)
-18.57%
Free cash flow per share (TTM)
-2.047
Growth
Revenue change (TTM)
-9.94%
Earnings per share change (TTM)
-20.82%
3-year revenue growth (CAGR)
-10.18%
10-year revenue growth (CAGR)
-7.99%
3-year earnings per share growth (CAGR)
-9.67%
10-year earnings per share growth (CAGR)
2.00%
What the Analysts think about Enanta
Analyst ratings (Buy, Hold, Sell) for Enanta stock.
Bulls say / Bears say
As of June 30, 2025, Enanta held $204.1 million in cash, cash equivalents and short-term marketable securities, which management expects will fund operations into fiscal 2028, reducing near-term financing risk (Business Wire)
Enanta met its target enrollment of 180 patients in the Phase 2 RSVHR study of its lead RSV candidate zelicapavir in Q2 2025 and is on track to report topline data in late 3Q 2025, a key value-inflection point (Business Wire)
AbbVie’s FDA approval in June 2025 of an expanded acute HCV indication for MAVYRET® (glecaprevir/pibrentasvir), one of Enanta’s core discovery products, potentially expands royalty revenue through Enanta’s retained interest (AbbVie)
Royalty revenue from AbbVie’s MAVYRET®/MAVIRET® fell 13% year-over-year to $14.9 million in Q2 FY2025, with 54.5% of royalties ceded to OMERS under a sale transaction, constraining net cash inflows (Business Wire)
Enanta reported a net loss of $22.6 million for the quarter ended March 31, 2025, underscoring ongoing cash burn despite narrowing losses (Business Wire)
Enanta’s immunology programs remain preclinical, with IND-enabling studies for its KIT inhibitor and STAT6 development candidate selection not expected until H2 2025, exposing investors to high early-stage pipeline risk (Business Wire)
Data summarised monthly by Lightyear AI. Last updated on 9 Oct 2025.
Enanta Financial Performance
Revenues and expenses
Enanta Earnings Performance
Company profitability
Enanta News
AllArticlesVideos
Enanta Pharmaceuticals to Present Data for Zelicapavir and EDP-323, Two Candidates in Development for the Treatment of Respiratory Syncytial Virus (RSV) at IDWeek™ 2025
Business Wire7 days ago
Enanta Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Business Wire2 weeks ago
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Enanta stock?
Enanta (ENTA) has a market cap of $307M as of October 13, 2025.
What is the P/E ratio for Enanta stock?
The price to earnings (P/E) ratio for Enanta (ENTA) stock is 0 as of October 13, 2025.
Does Enanta stock pay dividends?
No, Enanta (ENTA) stock does not pay dividends to its shareholders as of October 13, 2025.
When is the next Enanta dividend payment date?
Enanta (ENTA) stock does not pay dividends to its shareholders.
What is the beta indicator for Enanta?
Enanta (ENTA) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.